Biotech Values

[DewDiligence]

MYL at JPM ridiculed Teva's PlosOne study, saying that what happens in healthy mice is not indicative of what happens in humans with MS and that the discrepancies cited in the paper have no clinical significance.

This sounds to be like an admission that there are indeed differences between the two products, although MYL claims that it has modified Natco's formulation.